Page 1 | Search Results | Blood Advances | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding

Maureane Hoffman

Blood Adv (2021) 5 (18): 3736.

https://doi.org/10.1182/bloodadvances.2021004802

Published: 2021

Includes: Supplemental data

Journal Articles

Population pharmacokinetics of the von Willebrand factor–factor VIII interaction in patients with von Willebrand disease

Laura H. Bukkems, Jessica M. Heijdra, Nico C. B. de Jager, Hendrika C. A. M. Hazendonk, Karin Fijnvandraat, Karina Meijer, Jeroen C. J. Eikenboom, Britta A. P. Laros-van Gorkom, Frank W. G. Leebeek, Marjon H. Cnossen, Ron A. A. Mathôt

Blood Adv (2021) 5 (5): 1513–1522.

https://doi.org/10.1182/bloodadvances.2020003891

Published: 2021

Includes: Supplemental data

Journal Articles

Molecular coevolution of coagulation factor VIII and von Willebrand factor

Philip M. Zakas, Christopher W. Coyle, Anja Brehm, Marion Bayer, Barbara Solecka-Witulska, Caelan E. Radford, Christine Brown, Kate Nesbitt, Courtney Dwyer, Christoph Kannicht, H. Trent Spencer, Eric A. Gaucher, Christopher B. Doering, David Lillicrap

Blood Adv (2021) 5 (3): 812–822.

https://doi.org/10.1182/bloodadvances.2020002971

Published: 2021

Includes: Supplemental data

Journal Articles

Gut dysbiosis modulates the immune response to factor VIII in murine hemophilia A

Julie Tarrant, Matthew Cormier, Kate Nesbitt, Courtney Dwyer, Christine Hough, David Lillicrap

Blood Adv (2020) 4 (12): 2644–2655.

https://doi.org/10.1182/bloodadvances.2019001144

Published: 2020

Includes: Supplemental data

Journal Articles

Laboratory monitoring of hemophilia A treatments: new challenges

Peter J. Lenting

Blood Adv (2020) 4 (9): 2111–2118.

https://doi.org/10.1182/bloodadvances.2019000849

Published: 2020

Journal Articles

von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD

Ferdows Atiq, Lisette M. Schütte, Agnes E. M. Looijen, Johan Boender, Marjon H. Cnossen, Jeroen Eikenboom, Moniek P. M. de Maat, Marieke J. H. A. Kruip, Frank W. G. Leebeek

Blood Adv (2019) 3 (24): 4147–4154.

https://doi.org/10.1182/bloodadvances.2019000863

Published: 2019

Journal Articles

New therapies for von Willebrand disease

Pier Mannuccio Mannucci

Blood Adv (2019) 3 (21): 3481–3487.

https://doi.org/10.1182/bloodadvances.2019000368

Published: 2019

Journal Articles

Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue

Wojciech Jankowski, Joseph McGill, H. A. Daniel Lagassé, Stepan Surov, Gary Bembridge, Campbell Bunce, Edward Cloake, Mark H. Fogg, Katarzyna I. Jankowska, Abdul Khan, Joseph Marcotrigiano, Mikhail V. Ovanesov, Zuben E. Sauna

Blood Adv (2019) 3 (17): 2668–2678.

https://doi.org/10.1182/bloodadvances.2019000338

Published: 2019

Includes: Supplemental data

Journal Articles

Infused factor VIII–expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A

Randolph B. Lyde, Hyun Sook Ahn, Karen K. Vo, Danuta J. Jarocha, John Tkaczynski, Elsa Treffeisen, Spencer K. Sullivan, Rodney M. Camire, Denise E. Sabatino, Deborah L. French, Mortimer Poncz

Blood Adv (2019) 3 (9): 1368–1378.

https://doi.org/10.1182/bloodadvances.2017007914

Published: 2019

Includes: Supplemental data

Journal Articles

Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice

Rikke Stagaard, Carsten Dan Ley, Kasper Almholt, Lisbeth Høier Olsen, Tom Knudsen, Matthew J. Flick

Blood Adv (2018) 2 (22): 3126–3136.

https://doi.org/10.1182/bloodadvances.2018024851

Published: 2018

Journal Articles

Gene therapy in hemophilia A: a cost-effectiveness analysis

Nicoletta Machin, Margaret V. Ragni, Kenneth J. Smith

Blood Adv (2018) 2 (14): 1792–1798.

https://doi.org/10.1182/bloodadvances.2018021345

Published: 2018

Journal Articles

HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study

Christine L. Kempton, Amanda B. Payne

Blood Adv (2018) 2 (14): 1750–1755.

https://doi.org/10.1182/bloodadvances.2018019323

Published: 2018

Journal Articles

FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity

Ruth A. Ettinger, Joseph A. Liberman, Devi Gunasekera, Komal Puranik, Eddie A. James, Arthur R. Thompson, Kathleen P. Pratt

Blood Adv (2018) 2 (4): 309–322.

https://doi.org/10.1182/bloodadvances.2017013482

Published: 2018

Includes: Supplemental data

Journal Articles

CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells

Sylvain Meunier, Catherine Menier, Elodie Marcon, Sébastien Lacroix-Desmazes, Bernard Maillère

Blood Adv (2017) 1 (21): 1842–1847.

https://doi.org/10.1182/bloodadvances.2017008706

Published: 2017

Includes: Supplemental data

Journal Articles

The impact of von Willebrand factor on factor VIII memory immune responses

Juan Chen, Jocelyn A. Schroeder, Xiaofeng Luo, Qizhen Shi

Blood Adv (2017) 1 (19): 1565–1574.

https://doi.org/10.1182/bloodadvances.2017009209

Published: 2017

Includes: Supplemental data

NARROW

Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding

Population pharmacokinetics of the von Willebrand factor–factor VIII interaction in patients with von Willebrand disease

Molecular coevolution of coagulation factor VIII and von Willebrand factor

Gut dysbiosis modulates the immune response to factor VIII in murine hemophilia A

Laboratory monitoring of hemophilia A treatments: new challenges

von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD

New therapies for von Willebrand disease

Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue

Infused factor VIII–expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A

Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice

Gene therapy in hemophilia A: a cost-effectiveness analysis

HLA-DRB1–factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study

FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity

CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells

The impact of von Willebrand factor on factor VIII memory immune responses

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only